K-Gem Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combined action of these agents provides a complementary mechanism to effectively lower blood glucose levels in patients inadequately controlled by diet and exercise alone. K-Gem Tablet is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust the dosage appropriately and minimize the risk of hypoglycemia. Contraindications include severe renal impairment, metabolic acidosis, and known hypersensitivity to either component. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Patients should be advised to report symptoms of hypoglycemia promptly. K-Gem Tablet should be used under medical supervision with periodic assessment of renal function and glycemic status to ensure safe and effective therapy.